GURC: A Study of Participants With Advanced Prostate Cancer in Canada

Sponsor
Janssen Inc. (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT03501173
Collaborator
(none)
377
22
63.2
17.1
0.3

Study Details

Study Description

Brief Summary

The purpose of this study is to document the course of advanced prostate cancer in Canada in terms of disease progression, real-world treatment, and patient management.

Condition or Disease Intervention/Treatment Phase
  • Other: Standard of Care

Study Design

Study Type:
Observational
Actual Enrollment :
377 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Multicentre Cohort Study of Patients With Advanced Prostate Cancer in Canada
Actual Study Start Date :
Apr 12, 2018
Anticipated Primary Completion Date :
Jul 7, 2023
Anticipated Study Completion Date :
Jul 20, 2023

Arms and Interventions

Arm Intervention/Treatment
Metastatic Castrate-Sensitive Prostate Cancer (mCSPC)

Participants will be defined as having mCSPC if there is a new mCSPC diagnosis in the past 6 months, documented metastatic prostate cancer, no more than 12 months of androgen deprivation therapy (ADT) in any setting and no more than 6 months of systemic treatment for mCSPC (example, next generation androgen receptor targeted therapy or chemotherapy).

Other: Standard of Care
Participants will not receive any intervention in this study. Participants will receive standard of care therapy.

Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

Participants will be defined as having mCRPC if there is mCRPC diagnosis at any time, documented metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 2 criteria (elevated prostate specific antigen [PSA] despite testosterone less than [<]50 nanogram per deciliter [ng/dL] [<1.7 nano moles per liter{nmol/L}]), the first treatment for mCRPC was started in the past 6 months or is scheduled to begin.

Other: Standard of Care
Participants will not receive any intervention in this study. Participants will receive standard of care therapy.

NonMetastatic Castrate-Resistant Prostate Cancer (nmCRPC)

Participants will be defined as having nmCRPC if there is nmCRPC diagnosis at any time, documented non-metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 3 criteria (elevated PSA despite testosterone <50 ng/dL [<1.7 nmol/L]). nmCRPC, defined as a prostate specific antigen doubling time (PSADT) of less than or equal to 12 months, or beginning next generation ARAT for nmCRPC.

Other: Standard of Care
Participants will not receive any intervention in this study. Participants will receive standard of care therapy.

mCRPC (Treatment-experienced in the nmCRPC or mCSPC Setting)

Participants will be defined as having mCRPC (treatment-experienced in the nmCRPC or mCSPC setting) if there is nmCRPC diagnosis at any time, documented non-metastatic prostate cancer, documented metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 2 criteria (elevated PSA despite testosterone <50 ng/dL [<1.7nmol/L]), the first treatment for mCRPC clinical state was started in the past 6months or is scheduled to begin, disease progression occurred while receiving active treatment (ARAT or chemotherapy) in the prior nmCRPC or mCSPC clinical state.

Outcome Measures

Primary Outcome Measures

  1. Time to Prostate Specific Antigen (PSA) Progression [Approximately up to 5 years]

    Time to PSA progression is defined as the time interval from the date of start of study enrollment to the date of first evidence of PSA progression. In participants whose PSA level has decreased, PSA progression is defined as at least a 25 percent (%) increase from nadir (lowest value including the most recent value prior to study enrollment) and an increase in the absolute value of 2 nanogram per milliliter (ng/mL) or greater, confirmed by a subsequent measurement at least 3 weeks after the increase. In participants whose PSA level has not decreased, PSA progression is defined as at least a 25% increase from the most recent value prior to study enrollment and an increase in the absolute value of 2 ng/mL or greater after 12 weeks.

  2. Time to Radiographic Evidence of Disease Progression [Approximately up to 5 years]

    Time to radiographic evidence of disease progression is defined as the time interval from the date of start of study treatment to the date of first appearance of 2 or more new bone lesions on bone scan or enlargement of a soft tissue lesion using the Response Evaluation Criteria in Solid Tumors (RECIST).

  3. Time to Skeletal-Related Events [Approximately up to 5 years]

    Time to skeletal-related events is defined as the time interval from the date of start of study treatment to the date of first skeletal-related event.

  4. Time to Death [Approximately up to 5 years]

    Time to death is defined as the time interval from the date of start of study enrollment to death.

  5. Number of Participants with Different Primary Causes of Death [Approximately up to 5 years]

    The number of participants with different primary causes of death will be reported.

  6. Time to Progression from mCSPC to mCRPC in Participants with mCSPC [Approximately up to 5 years]

    In participants with mCSPC, time to progression from mCSPC to mCRPC is defined as the time interval which is either calculated from date when mCSPC was first documented or from the date of start of study treatment, if participant receives treatment for mCSPC to the progression to mCRPC.

  7. Time from Biochemical Recurrence (BCR) to Nonmetastatic Castrate-Resistant Prostate Cancer (nmCRPC) and nmCRPC to mCRPC [Approximately up to 5 years]

    In participants with mCRPC, time from BCR to nmCRPC and nmCRPC to mCRPC will be analyzed retrospectively. BCR is defined as PSA greater than (>)0.2 nanogram per milliliter (ng/mL) after radical prostatectomy and PSA >2 ng/mL above the nadir (lowest value including the most recent value prior to study enrollment) after radical radiotherapy.

  8. Number of Participants with PSA Testing from BCR to nmCRPC and nmCRPC to mCRPC, in Participants with mCRPC [Approximately up to 5 years]

    In participants with mCRPC, number of participants having PSA testing from BCR to nmCRPC and nmCRPC to mCRPC will be reported.

  9. Number of Participants with Frequency of Imaging from Time of BCR to nmCRPC and nmCRPC to mCRPC [Approximately up to 5 years]

    In participants with non metastatic castrateresistant prostate cancer (nmCRPC), number of participants having imaging from BCR to nmCRPC and mCRPC to nmCRPC will be reported.

  10. PSA Level at Start of Androgen Deprivation Therapy (ADT) in Participants with mCRPC [Approximately up to 5 years]

    In participants with mCRPC, PSA level at start of ADT will be reported.

  11. PSA Doubling Time (PSADT) at the Detection of Castration Resistance in Participants with mCRPC [Approximately up to 5 years]

    In participants with mCRPC, PSADT at the detection of castration resistance will be reported. PSADT is the length of time it takes for a PSA to double based on an exponential growth pattern.

  12. Time from nmCRPC to High-Risk (HR) nmCRPC [Approximately up to 5 years]

    Time from nmCRPC to HR nmCRPC is defined as prostate specific antigen doubling time (PSADT) less than or equal to (<=) 10 months.

  13. Time from ADT Initiation to nmCRPC [Approximately up to 5 years]

    Time from ADT initiation to nmCRPC will be reported.

  14. Median Absolute prostate specific antigen (PSA) at onset of HR-nmCRPC [Approximately up to 5 years]

    Median absolute PSA at onset of HR-nmCRPC will be reported.

  15. Time to Initiation of Subsequent Prostate Cancer Treatment [Approximately up to 5 years]

    Time to initiation of subsequent prostate cancer treatment is defined as the time interval from the date of start of study treatment to the date of start of subsequent prostate cancer treatment.

  16. Duration of Each Therapy [Approximately up to 5 years]

    Duration for each therapy will be reported for all participants.

  17. Percentage of Participants Receiving Chemotherapy, Other Drug Treatments, or no Drug Treatment [Approximately up to 5 years]

    Percentage of participants receiving chemotherapy, other drug treatments, or no drug treatment, will be reported for all participants.

  18. Time to Treatment Initiation [Approximately up to 5 years]

    Time to treatment initiation, will be reported for all participants.

  19. Time to Dose Modification [Approximately up to 5 years]

    Time to dose modification, will be reported for all participants.

  20. Number of Participants who Switch the Treatment [Approximately up to 5 years]

    Number of participants who switch the treatment, will be reported.

  21. Number of Participants who Discontinued the Treatment [Approximately up to 5 years]

    Number of participants who discontinued the treatment, will be reported.

  22. Most Common Sequences for Lines of Therapy in Participants with mCRPC [Approximately up to 5 years]

    In participants with mCRPC, most common sequences for lines of therapy will be reported.

  23. Number of Participants Retreated with Docetaxel in Participants with mCRPC [Approximately up to 5 years]

    In participants with mCRPC, number of participants having retreatment with docetaxel will be reported.

  24. Percentage of Participant with Radiographic Imaging Modality [Approximately up to 5 years]

    Percentage of participants with radiographic imaging modality which includes bone scan, magnetic resonance imaging, ultrasound, X-ray will be reported.

  25. Number of Days Hospitalized for Prostate Cancer or Treatment of Prostate Cancer [Approximately up to 5 years]

    Number of days for which participant was hospitalized for prostate cancer or treatment of prostate cancer, will be reported for all participants.

  26. Number of Visits to Emergency Department for Prostate Cancer or Treatment of Prostate Cancer [Approximately up to 5 years]

    Number of visits to emergency department for prostate cancer or treatment of prostate cancer, will be reported for all participants.

  27. Number of Outpatient Visits to Specialists Involved in Management of Prostate Cancer [Approximately up to 5 years]

    Number of outpatient visits to specialists (urologist, medical oncologist, uro-oncologist, radiation oncologist) involved in management of prostate cancer, will be reported for all participants.

  28. Dates of Genomic or Genetic Testing [Approximately up to 5 years]

    Dates of genomic or genetic testing (including dopa-responsive dystonia [DRD]/ homologous recombination repair [HRR]/ breast cancer gene-1 [BRCA1]/ BRCA2/ataxia-telangiesctasia mutated [ATM]/partner and localizer of the BRCA2 gene [PALB2]/ androgen receptor [AR]) will be reported.

  29. Types of Genomic or Genetic Testing [Approximately up to 5 years]

    Types of genomic or genetic testing (including DRD/HRR/ BRCA1/ BRCA2/ATM /PALB2/AR) will be reported.

  30. Charlson Comorbidity Index Score [Approximately up to 5 years]

    Charlson Comorbidity Index score will be summarized descriptively. The Charlson Comorbidity Index is a 19-item measure assessing comorbid conditions. The total possible score on the Charlson Comorbidity Index ranges from 0 to 37. If a condition is not present, the score for that condition is zero. The higher scores indicate greater comorbidity.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Participant must have a confirmed diagnosis of adenocarcinoma of the prostate

  • Participant must have prostate cancer, as follows: a) nonmetastatic castrate-resistant prostate cancer (nmCRPC): nmCRPC diagnosis at any time; documented castration resistance per Prostate Cancer Working Group 3 criteria23 (elevated prostate specific antigen [PSA] despite testosterone less than (<) 50 nanograms per deciliter [ng/dL] [<1.7 nano moles per liter {nmol/L}]); Negative for metastases on conventional imaging (computerized tomography, Magnetic resonance imaging, bone scans); Prostate specific antigen doubling time (PSADT) less than equal to (<=) 12 months within the last 6 months or beginning treatment with approved next-generation ARAT for treatment of nmCRPC; b) Metastatic castrate-sensitive prostate cancer (mCSPC): new mCSPC diagnosis in the past 6 months (can be de novo or primary progressive recurrent following local radical therapy); documented metastatic prostate cancer; no more than 12 months of androgen deprivation therapy (ADT) in any setting; no more than 6 months of systemic treatment for mCSPC (example, approved next generation androgen receptor targeted therapy or chemotherapy]); c) Metastatic castrate-resistant prostate cancer (mCRPC): mCRPC diagnosis at any time; documented metastatic prostate cancer; documented castration resistance per Prostate Cancer Working Group 2 criteria (elevated prostate specific antigen [PSA] despite testosterone less than [<]50 nanogram per deciliter [ng/dL] [<1.7 nmol/L]); the first treatment for mCRPC was started in the past 6 months or is scheduled to begin; d) mCRPC (treatment-experienced in the nmCRPC or mCSPC setting): mCRPC diagnosis at any time; documented metastatic prostate cancer; documented castration resistance per Prostate Cancer Working Group 2 criteria (elevated PSA despite testosterone <50 ng/dL [<1.7 nmol/L]); the first treatment for mCRPC clinical state was started in the past 6 months or is scheduled to begin; disease progression occurred while receiving active treatment (androgen receptor-axis therapy [ARAT] or chemotherapy) in the prior nmCRPC or mCSPC clinical state

  • Participant must have a life expectancy of more than 6 months

  • Participant must sign (and/or their legally acceptable representative, if applicable) a participation agreement/informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements and/or sponsor policy

Exclusion Criteria:
  • At the time of screening, patient is currently enrolled in other Janssen sponsored clinical study (any indication) or an interventional clinical trial investigating a non Health Canada approved drug and/or procedure for the treatment and/or monitoring of prostate cancer (Janssen or non-Janssen company sponsored)

  • Participant is currently enrolled in any observational study sponsored or managed by a Janssen company

Contacts and Locations

Locations

Site City State Country Postal Code
1 Tom Baker Cancer Center Calgary Alberta Canada T2N 4N2
2 Prostate Cancer Centre Calgary Alberta Canada T2V 1P9
3 University of Alberta Edmonton Alberta Canada T6G 1Z2
4 Abbotsford Regional Hospital and Cancer Centre BC Cancer Agency Abbotsford British Columbia Canada V2S 0C2
5 British Columbia Cancer Agency(BCCA)-Sindi Ahluwalia Hawkins Centre for the Southern Interior(CSI) Kelowna British Columbia Canada V1Y 5L3
6 Vancouver General Hospital / Vancouver Prostate Centre Vancouver British Columbia Canada V5Z 1M9
7 BC Cancer Agency - Vancouver BC Vancouver British Columbia Canada V5Z 4E6
8 British Columbia Cancer Agency - Vancouver Island Centre Victoria British Columbia Canada V8R 6V5
9 Cancer Care Manitoba Winnipeg Manitoba Canada R3E 0V9
10 Queen Elizabeth II - Health Sciences Centre Halifax Nova Scotia Canada B3H 2Y9
11 G. Kenneth Jansz Medicine Burlington Ontario Canada L7N 3V2
12 Research St. Joseph's - Hamilton Hamilton Ontario Canada L8N 4A6
13 Hamilton Health Sciences Corporation Hamilton Ontario Canada L8V 5C2
14 Lawson Health Research Institute London Ontario Canada N6A 5W9
15 Credit Valley Hospital Mississauga Ontario Canada L5M 2V8
16 The Ottawa Hospital Cancer Centre Ottawa Ontario Canada K1H 8L6
17 Scarborough Health Network Toronto Ontario Canada M1VOE3
18 Princess Margaret Hospital Toronto Ontario Canada M5G 2M9
19 Urology South Shore Research Greenfield Park Quebec Canada J4V 2H3
20 CHUM - Centre hospitalier universitaire de Montreal Montreal Quebec Canada H2X 0A9
21 Jewish General Hospital Montreal Quebec Canada H3T 1E2
22 CHU de Québec Université Laval Quebec Canada G1R 2J6

Sponsors and Collaborators

  • Janssen Inc.

Investigators

  • Study Director: Janssen Inc. Clinical Trial, Janssen Inc.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Janssen Inc.
ClinicalTrials.gov Identifier:
NCT03501173
Other Study ID Numbers:
  • CR108454
  • 212082PCR4049
First Posted:
Apr 18, 2018
Last Update Posted:
Aug 3, 2022
Last Verified:
Aug 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 3, 2022